Therapeutic targets and inhibitors
| Target/Inhibitor | Examples of preclinical sensitivity | References |
|---|---|---|
| NHE1 | ||
| Amiloride | Mammary, prostate, gastric, hepatoma | [104] |
| Ethylisopropylamiloride (EIPA) | Bladder, breast cancer | [109] |
| Dimethylamiloride (DMA) | Bladder, breast cancer | [109] |
| Hexamethyleneamiloride (HMA) | Leukemia | [110] |
| Cariporide | Leukemia, cholangiocarcinoma | [12, 96–103] |
| Phx-3 | Gastric cancer | [111, 12] |
| MCT1/MCT4 | ||
| α-cyano-4-hydroxycinnamate | Lung cancer | [116] |
| AZD 3965 | Small cell lung cancer | [131] |
| AR-C155858 | Rat transformed fibroblasts | [121] |
| V-ATPases | ||
| Balifomycin C | Pancreatic cancer, colon cancer | [157, 159] |
| Concanamycin A | Submandibular cancer | [162] |
| Esomerprazole | Breast cancer, esophageal cancer | [171, 172] |
| Omeprazole | Melanoma | [168, 169] |
| Lansoprazole | Pancreatic cancer, breast cancer | [166, 170] |
| CAIX | ||
| Indisulam | Lung cancer | [208] |
| VII/20 Monoclonal antibody | Colon cancer | [198] |